News
Public · Published
Guggenheim maintains Biogen at Buy, raises price target to $300 from $280
Guggenheim kept its Buy rating on Biogen and raised its price target to $300 from $280, a 7.1% increase. The new target is 18.3% above Biogen's Oct. 30 closing price of $253.62.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on Biogen and raised its price target to $300 from $280, a 7.1% increase. The new target is 18.3% above Biogen’s Oct. 30 closing price of $253.62.
Confirmed
Global impact / market context
A higher analyst target signals greater expected share-price upside in Guggenheim’s view, but it does not change Biogen’s sales, costs, or cash directly. Investors may use the revised target when judging the stock, while remembering it is an estimate rather than a guaranteed outcome.
Analyst inference
The article lists five other recent analyst targets, ranging from $238 to $280, so Guggenheim’s new $300 target sits above that stated range. The differing ratings and targets show analysts hold varied views; the article reports no resulting share-price reaction.
Confirmed
What to watch
- Compare future analyst targets and ratings with Guggenheim’s $300 target to see whether other published views move closer to, or farther from, its estimate. Analyst inference
- Check Biogen’s later reported business results for evidence that sales, costs, or cash generation support or challenge expectations implied by analysts’ views. Analyst inference
- The article gives no follow-up company results or share-price reaction, so whether the higher target changes investor positioning remains unknown. Confirmed
Evidence
- Original source link unavailable